Atlas Trials

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Clinical trial NCT05425719 · COMPLETED

Trial details

NCT number
NCT05425719
Sponsor
MediBeacon
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Kidney Disease
Start date
2022-06-14
Primary completion
2023-02-15
Enrollment
249

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.